Related Experiment Videos
Tumor-reactive superantigens suppress tumor growth in humanized SCID mice
P A Lando1, M Dohlsten, L Ohlsson
1Department of Tumor Immunology, Wallenberg Laboratory, University of Lund, Sweden.
Abstract:
Superantigens are extremely potent activators of T lymphocytes. To develop a tumor-reactive superantigen for cancer therapy, we made a recombinant fusion protein of the superantigen staphylococcal enterotoxin A (SEA) and the Fab region of the C242 monoclonal antibody (C242Fab-SEA), which recognize human colon carcinoma cells. The therapeutic effect of C242Fab-SEA on colon-cancer growth was examined in lymphocyte-engrafted humanized SCID mice bearing intraperitoneally growing Colo205 colon carcinomas. i.v. injections of C242Fab-SEA significantly inhibited tumor growth. The anti-tumor effect required the presence of human T cells in the SCID mice. Optimal therapeutic effects were seen with C242Fab-SEA, but not with C242Fab fragment or SEA alone, demonstrating that both entities of the fusion protein were required. C242Fab-SEA-treated tumors showed a massive infiltration of T cells in the tumor parenchyme, and was accompanied by enhanced expression of ICAM-I and HLA-DR on the tumor cells. The results demonstrate that Fab-SEA fusion proteins convey superantigenicity on tumor cells which evoke T-cell-dependent suppression of tumor growth.
Insights
Researchers developed a novel fusion protein linking staphylococcal enterotoxin A (SEA) to an antibody fragment to target colon cancer. This engineered superantigen effectively inhibited tumor growth in mice by activating T cells, showing promise for cancer therapy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Superantigens are potent T-lymphocyte activators.
- Targeting T cells offers a promising avenue for cancer therapy.
- Developing tumor-specific immune responses is crucial for effective cancer treatment.
Purpose of the Study:
- To create a tumor-reactive superantigen for cancer therapy.
- To evaluate the anti-tumor efficacy of a novel fusion protein, C242Fab-SEA.
- To investigate the mechanism of T-cell-mediated anti-tumor activity.
Main Methods:
- Constructed a recombinant fusion protein (C242Fab-SEA) combining staphylococcal enterotoxin A (SEA) and a colon carcinoma-targeting antibody fragment (C242Fab).
- Administered C242Fab-SEA intravenously to humanized SCID mice bearing human colon carcinoma xenografts (Colo205).
- Assessed tumor growth inhibition, T-cell infiltration, and expression of ICAM-1 and HLA-DR.
Main Results:
- C242Fab-SEA significantly inhibited colon cancer growth in vivo.
- The anti-tumor effect was dependent on the presence of human T cells.
- Both the antibody fragment and SEA components of the fusion protein were essential for optimal therapeutic effect.
- Tumors treated with C242Fab-SEA exhibited increased T-cell infiltration and enhanced ICAM-1 and HLA-DR expression on tumor cells.
Conclusions:
- Fab-SEA fusion proteins can confer superantigenicity to tumor cells.
- This approach effectively elicits T-cell-dependent tumor suppression.
- C242Fab-SEA represents a potential new strategy for colon cancer immunotherapy.